Список литературы к Главе 17

1. Hamblin T.J. Autoimmune complications of chronic lymphocytic leukemia // Semin. Oncol. 2006. Vol. 33, N 2. P. 230–239.

2. Hodgson K. et al. Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment // Br. J. Haematol. 2011. Vol. 154, N 1. P. 14–22.

3. Diehl L.F., Ketchum L.H. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia // Semin. Oncol. 1998. Vol. 25, N 1. P. 80–97.

4. Ebbe S., Wittels B., Dameshek W. Autoimmune thrombocytopenic purpura («ITP» type) with chronic lymphocytic leukemia // Blood. 1962. Vol. 19. P. 23–37.

5. Hallek M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL // Blood. 2018. Vol. 131, N 25. P. 2745–2760.

6. Visco C., Rodeghiero F. Immune thrombocytopenia in lymphoproliferative disorders // Hematol. Oncol. Clin. North Am. 2009. Vol. 23, N 6. P. 1261–1274.

7. Zent C.S. et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis // Leuk. Lymphoma. 2009. Vol. 50, N 8. P. 1261–1268.

8. Pettitt A.R. et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial // J. Clin. Oncol. 2012. Vol. 30, N 14. P. 1647–1655.

9. Mauro F.R. et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features // Blood. 2000. Vol. 95, N 9. P. 2786–2792.

10. Zent C.S. et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma // Br. J. Haematol. 2008. Vol. 141, N 5. P. 615–621.

11. Moreno C. et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance // Blood. 2010. Vol. 116, N 23. P. 4771–4776.

12. Borthakur G. et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors // Br. J. Haematol. 2007. Vol. 136, N 6. P. 800–805.

13. Dearden C. et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia // Blood. 2008. Vol. 111, N 4. P. 1820–1826.

14. Jung M., Rice L. Unusual autoimmune nonhematologic complications in chronic lymphocytic leukemia // Clin. Lymphoma Myeloma Leuk. 2011. Vol. 11. P. S10–S13.

15. Alattar M.L. et al. Bleeding diathesis associated with acquired von Willebrand syndrome in three patients with chronic lymphocytic leukemia // Leuk. Lymphoma. 2015. Vol. 56, N 12. P. 3452–3454.

16. Tandra P. et al. Autoimmune cytopenias in chronic lymphocytic leukemia, facts and myths // Mediterr. J. Hematol. Infect. Dis. 2013. Vol. 5, N 1. Article ID e2013068.

17. Konichi­Dias R.L. et al. Paraneoplastic pemphigus associated with chronic lymphocytic leukemia: a case report // J. Med. Case Rep. 2018. Vol. 12, N 1. P. 252.

18. Cao L. et al. Chronic lymphocytic leukemia­associated paraneoplastic pemphigus: potential cause and therapeutic strategies // Sci. Rep. 2020. Vol. 10, N 1. Article ID 16357.

19. Abdulkareem A. et al. Refractory abdominal pain in a patient with chronic lymphocytic leukemia: be wary of acquired angioedema due to C1 esterase inhibitor deficiency // Case Rep. Hematol. 2018. Vol. 2018. Article ID 7809535.

20. Mohyuddin G., Rabinowitz I. A patient with chronic lymphocytic leukemia and acquired angioedema: correlation of clinical and biochemical response to CLL therapy // Ecancermedicalscience. 2013. Vol. 7. P. 292.

21. Wanchoo R. et al. Renal involvement in chronic lymphocytic leukemia // Clin. Kidney J., 2018. Vol. 11, N 5. P. 670–680.

22. Beaume A. et al. High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in B­cell chronic lymphocytic leukemia // Blood. 1994. Vol. 84, N 4. P. 1216–1219.

23. Stevenson F.K. et al. Extracellular idiotypic immunoglobulin arising from human leukemic B lymphocytes // J. Exp. Med. 1980. Vol. 152, N 6. P. 1484–1496.

24. Bröker B.M. et al. Chronic lymphocytic leukemia (CLL) cells secrete multispecific autoantibodies // J. Autoimmun. 1988. Vol. 1, N 5. P. 469–481.

25. Galletti J. et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia // J. Immunol. 2008. Vol. 181, N 5. P. 3674–3683.

26. Hall A.M. et al. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells // Blood. 2005. Vol. 105, N 5. P. 2007–2015.

27. Strati P., Caligaris­Cappio F. A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy? // Curr. Opin. Oncol. 2011. Vol. 23, N 5. P. 455–460.

28. Ward F.J. et al. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia // Blood. 2008. Vol. 111, N 2. P. 680–687.

29. Gorgun G. et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells // J. Clin. Invest. 2005. Vol. 115, N 7. P. 1797–1805.

30. Beyer M. et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine // Blood. 2005. Vol. 106, N 6. P. 2018–2025.

31. Wright G.P., Ehrenstein M.R., Stauss H.J. Regulatory T­cell adoptive immunotherapy: potential for treatment of autoimmunity // Expert Rev. Clin. Immunol. 2011. Vol. 7, N 2. P. 213–225.

32. Lad D.P. et al. Regulatory T­cell and T­helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias // Leuk. Lymphoma. 2015. Vol. 56, N 8. P. 2424–2428.

33. Grandjenette C. et al. Expression of functional toll­like receptors by B­chronic lymphocytic leukemia cells // Haematologica. 2007. Vol. 92, N 9. P. 1279–1281.

34. Muzio M. et al. The role of toll­like receptors in chronic B­cell malignancies // Leuk. Lymphoma. 2009. Vol. 50, N 10. P. 1573–1580.

35. Barcellini W. et al. Toll­like receptor 4 and 9 expression in B­chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression // Leuk. Lymphoma. 2014. Vol. 55, N 8. P. 1768–1773.

36. Mockridge C.I. et al. Reversible anergy of sIgM­mediated signaling in the two subsets of CLL defined by VH­gene mutational status // Blood. 2007. Vol. 109, N 10. P. 4424–4431.

37. Bomben R. et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study // Br. J. Haematol. 2009. Vol. 144, N 4. P. 492–506.

38. Widhopf G.F. 2nd et al. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins // Blood. 2004. Vol. 104, N 8. P. 2499–2504.

39. Maura F. et al. Relevance of stereotyped B­cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia // PLoS One. 2011. Vol. 6, N 8. Article ID e24313.

40. Stamatopoulos K. et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations // Blood. 2007. Vol. 109, N 1. P. 259–270.

41. Maura F. et al. B­cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia // Am. J. Hematol. 2013. Vol. 88, N 1. P. 32–36.

42. Carli G. et al. Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome // Ann. Hematol. 2016. Vol. 95, N 6. P. 863–870.

43. Smirnova S.J. et al. Expansion of CD8+ cells in autoimmune hemolytic anemia // Autoimmunity. 2016. Vol. 49, N 3. P. 147–154.

44. Marron M.P. et al. Insulin­dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups // Hum. Mol. Genet. 1997. Vol. 6, N 8. P. 1275-1282.

45. Donner H. et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto’s thyroiditis and Addison’s disease // J. Clin. Endocrinol. Metab. 1997. Vol. 82, N 12. P. 4130–4132.

46. Pavkovic M. et al. CTLA­4 exon 1 polymorphism in patients with autoimmune blood disorders // Am. J. Hematol. 2003. Vol. 72, N 2. P. 147–149.

47. D’Abronzo L.S. et al. Analysis of polymorphisms of TNF­α, LT­α, IL­10, IL­12 and CTLA­4 in patients with warm autoimmune haemolytic anaemia // Int. J. Lab. Hematol. 2012. Vol. 34, N 4. P. 356–361.

48. Nagelkerke S.Q. et al. Red pulp macrophages in the human spleen are a distinct cell population with a unique expression of Fc­γ receptors // Blood Adv. 2018. Vol. 2, N 8. P. 941–953.

49. Ferrer G. et al. MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia // Leuk. Lymphoma. 2013. Vol. 54, N 9. P. 2016–2022.

50. Myint H. et al. Fludarabine­related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia // Br. J. Haematol. 1995. Vol. 91, N 2. P. 341–344.

51. Weiss R.B. et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia // J. Clin. Oncol. 1998. Vol. 16, N 5. P. 1885–1889.

52. Montillo M., Tedeschi A., Leoni P. Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia // Leuk. Lymphoma. 1994. Vol. 15, N 1–2. P. 187–188.

53. Barcellini W. et al. Relationship between autoimmune phenomena and disease stage and therapy in B­cell chronic lymphocytic leukemia // Haematologica. 2006. Vol. 91, N 12. P. 1689–1692.

54. Hallek M. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open­label, phase 3 trial // Lancet. 2010. Vol. 376, N 9747. P. 1164–1174.

55. Eichhorst B. et al. First­line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open­label, randomised, phase 3, non­inferiority trial // Lancet Oncol. 2016. Vol. 17, N 7. P. 928–942.

56. Montillo M. et al. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study // Blood Cancer J. 2017. Vol. 7, N 2. P. e524.

57. Vitale C. et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib // Haematologica. 2016. Vol. 101, N 6. P. e254–e258.

58. Rogers K.A. et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia // Leukemia. 2016. Vol. 30, N 2. P. 346–350.

59. Hampel P.J. et al. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre // Br. J. Haematol. 2018. Vol. 183, N 3. P. 421–427.

60. Candida V. et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib // Haematologica. 2016. Vol. 101, N 6. P. e254–e258.

61. Stilgenbauer S. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open­label, phase 2 study // Lancet Oncol. 2016. Vol. 17, N 6. P. 768–778.